TrialAllergy2018
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
M A Riedl et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
19 papers cite it
this paperpooled ittrialcites it